Dupixent (dupilumab) is a biologic approved for moderate-to-severe atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, COPD, and prurigo nodularis. Insurance coverage is generally available for all approved indications but always requires prior authorization. Dupixent is one of the highest-revenue specialty drugs, costing over $3,000 per month without insurance.

Key Facts

Dupixent is covered by most commercial and Medicare plans for all FDA-approved indications
Prior authorization is required by all plans, with documentation of disease severity and failed alternatives
Typical commercial plan copay: $0 to $200/month with Dupixent MyWay copay card
Sanofi/Regeneron's MyWay program covers up to $13,000/year in copay costs for eligible patients
Step therapy may require trying topical steroids, immunosuppressants, or phototherapy before approval
Without insurance, Dupixent costs approximately $3,300 to $3,700 per injection (every 2 weeks)

Open Enrollment Reminder

ACA marketplace enrollment runs November 1 to January 15. Medicare Annual Enrollment is October 15 to December 7. Compare formularies for your medications before choosing a plan.

Can't Afford Your Medication?
Find Patient Assistance Programs
Search manufacturer PAPs and nonprofit programs on OmniRx
Compare Cash Prices
Find the Lowest Pharmacy Price
Compare prices at pharmacies near you on RxGrab

Check Your Specific Plan's Formulary

Coverage varies by plan. Use our formulary checker tool to look up your exact copay and restrictions.

Open Formulary Checker

Frequently Asked Questions

How do I get Dupixent approved by insurance?

Your dermatologist or allergist submits prior authorization with documentation of your diagnosis, disease severity (EASI score for eczema, lung function for asthma), failed previous treatments, and photographs if applicable. Most insurers require that you have tried and failed at least one conventional therapy before approving Dupixent.

Does Medicare cover Dupixent?

Yes, Medicare Part D covers Dupixent for approved indications with prior authorization. The $2,000 annual out-of-pocket cap helps limit costs. However, specialty tier coinsurance (25% to 33%) can be significant before hitting the cap. Medicare patients cannot use manufacturer copay cards but may qualify for the Dupixent MyWay patient assistance program.

Is there a biosimilar for Dupixent?

As of 2026, there is no approved biosimilar for Dupixent (dupilumab). The earliest biosimilar entry is not expected until the late 2020s or early 2030s. In the meantime, the manufacturer's copay programs and patient assistance help manage out-of-pocket costs.

Related Resources

Get Formulary and Coverage Updates

Subscribe to receive alerts on formulary changes, new drug approvals, and insurance coverage updates.